Rucaparib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome.

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially severe hypersensitivity response to specific pharmacological agents that can manifest weeks after the initial exposure. Prior research has shown that this condition often presents with a triad of fever, cutaneous eruption, and internal organ involvement, which can lead to significant morbidity if not identified early. The clinical landscape for managing several solid tumor types has been significantly improved by the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors which target specific DNA repair deficiencies. These agents, including rucaparib, target DNA repair pathways to enhance therapeutic outcomes in oncology patients by inducing synthetic lethality in cells with homologous recombination deficiencies. Despite their efficacy, the emergence of rare systemic toxicities such as severe cutaneous adverse reactions requires careful documentation to ensure patient safety during long-term maintenance therapy. Understanding the full spectrum of adverse events associated with these specific enzymatic inhibitors is vital for oncologists and dermatologists alike. This absence of evidence motivated the detailed reporting of a novel case involving a severe systemic reaction potentially linked to rucaparib administration.

This case report documents the clinical presentation and resolution of a severe drug-induced hypersensitivity reaction in a 63-year-old woman undergoing maintenance therapy for a solid malignancy. The investigation focuses on the specific clinical markers of rucaparib-associated DRESS syndrome, including the onset of fever and the development of a diffuse rash. Researchers aimed to document the hematological abnormalities, specifically peripheral blood eosinophilia, that occurred following the initiation of this poly (ADP-ribose) polymerase (PARP) inhibitor in a clinical setting. The study also seeks to characterize the extent of systemic involvement by analyzing the elevation of liver enzymes and other hepatic transaminases during the acute phase of the reaction. Clinicians intended to demonstrate the effectiveness of a combined regimen of systemic and topical steroids in managing these complex symptoms. By providing a clear timeline of the reaction and recovery, the report serves to alert the medical community to this potential toxicity. This documentation is intended to improve the diagnostic accuracy and management strategies for oncology patients presenting with similar systemic symptoms.

The clinical team performed a longitudinal assessment of a 63-year-old female patient who was undergoing treatment with rucaparib for a solid tumor to monitor for adverse events. Diagnostic procedures involved the continuous monitoring of body temperature to detect the onset of fever and a detailed dermatological evaluation of the emerging rash. Laboratory technicians conducted serial blood tests to quantify the levels of circulating eosinophils and to monitor for significant hematologic shifts that might indicate an underlying hypersensitivity process. Hepatic function was assessed through the measurement of liver enzymes and metabolic panels to determine the degree of systemic organ involvement during the suspected drug reaction. The therapeutic intervention consisted of the administration of systemic corticosteroids to address the internal inflammatory response. Concurrently, topical steroids were applied to the cutaneous lesions to facilitate the resolution of the rash and improve patient comfort. Follow-up assessments were conducted to ensure the complete resolution of all symptoms and to confirm the absence of any long-term sequelae.

The patient exhibited a complex clinical profile characterized by the sudden onset of high fever and a widespread cutaneous rash shortly after beginning rucaparib therapy for her condition. Laboratory analysis confirmed the presence of significant eosinophilia, which is a hallmark of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Further diagnostic testing revealed a notable elevation in liver enzymes, indicating that the hypersensitivity reaction had progressed to involve internal organ systems beyond the initial cutaneous manifestations. The clinical team observed that these systemic and dermatological symptoms were potentially linked to the use of the poly (ADP-ribose) polymerase (PARP) inhibitor based on the temporal sequence. Upon the initiation of the steroid-based treatment protocol, the patient showed a rapid and sustained improvement in her physiological parameters. Both the fever and the rash resolved completely, and the liver enzyme levels returned to their baseline values following the intervention. The patient successfully recovered from the acute episode without experiencing any associated sequelae or permanent damage to her hepatic or hematologic systems.

This case highlights that rucaparib-associated DRESS syndrome is a severe, though infrequent, adverse event that must be considered when patients present with systemic symptoms during maintenance. The findings emphasize the necessity of including poly (ADP-ribose) polymerase (PARP) inhibitors in the list of potential triggers for severe drug-induced hypersensitivity reactions. Early recognition of the combination of fever, rash, and eosinophilia is essential for preventing the progression of organ dysfunction and ensuring the safety of oncology patients receiving targeted therapies. The study demonstrates that systemic and topical steroids remain an effective therapeutic strategy for resolving the manifestations of this syndrome. Clinicians should maintain a high index of suspicion for DRESS when managing patients on rucaparib who exhibit unexplained elevations in liver enzymes. Continued reporting of such idiosyncratic reactions will contribute to a more comprehensive understanding of the safety profile of targeted cancer therapies and help refine future clinical guidelines. This documentation ultimately supports the development of better monitoring protocols to ensure the safe administration of this enzymatic inhibitor in the treatment of solid tumors.